Global pharmaceutical company Piramal Pharma has announced its consolidated results for the second quarter (Q2) and half year (H1) ended 30th September 2022.
Key Highlights for H1FY23
▪ Revenue from operation grew by 11% to INR 3,202 Cr. versus INR 2,889 Cr. in H1FY22
o CDMO business grew by 12% YoY
o Complex hospital generic business grew by 11% YoY
o India consumer healthcare business grew by 12% YoY
▪ Normalised EBITDA in H1FY23 was INR 376 Cr. with EBITDA margin of 12%
▪ Capital Expenditure for H1FY23 was INR 427 Cr.
▪ Successfully cleared 22 regulatory inspections and 111 customer audits in H1FY23 ▪ Released Piramal Pharma Sustainability Report FY 2021-22
Nandini Piramal, Chairperson, Piramal Pharma said: “We announce our first results post demerger as an independent and focused pharma company. Over the last 10 years, we have made several strategic choices that have helped nurture and scale our business and establish Piramal Pharma (PPL) as a leading global pharmaceuticals player.
Piramal continued: "For the quarter and half year ended September 2022, our business has delivered a resilient performance despite multiple internal and external challenges. We expect to deliver a much improved performance in second half of the current financial year. Historically we have had a greater skew of sales and profits in the second half of the year and this year is no different. We have a vision to grow all our businesses to significant scale over the medium term and have strong growth levers in place for each of them. We continue to make investments to drive growth in these businesses.”
